Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients
Helicobacter · 2024
DOI: 10.1111/hel.13036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Helicobacter, 2024. Verfasst von Na Rae Lim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, St. Vincent Hospital, The Catholic University of Korea, Suwon, South Korea. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Dyspepsia, Gastritis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background/Aims Helicobacter pylori ( H. pylori ) infections can recur as either recrudescence or reinfection. At a time when the decline in the eradication rate is becoming evident, increases in the rate of recurrence are concerning. In addition, there are no guidelines for selecting an eradication regimen for H. pylori recurrence. Materials and Methods A total of 996 H. pylori ‐infected patients treated with proton‐pump inhibitor‐based triple eradication therapy between 2017 and 2022 were enrolled in the study, and successful eradication therapies were confirmed by the 13 C‐urea breath test. When retested within 1 year after successful eradication, analysis related to recrudescence was performed, and when retested after 1 year, analysis related to reinfection was performed. We reviewed the medical records and treatment outcomes of patients with H. pylori reinfection after successful eradication.
Results
The recrudescence rate was 3.9% (9/228), and the reinfection rate was 3.7% (36/970 person‐year). The frequency of reinfection reached 5.9% per person‐year within the first 24 months and 2.0%–2.4% per person‐year thereafter. In multivariate factor analysis, reinfection was significantly higher in patients with non‐ulcer dyspepsia ( p < 0.01). At first‐line therapy for reinfection, the eradication rate of standard triple therapy (STT) was 50.0% (16/32). The eradication rate of second‐line bismuth quadruple therapy was 81.3% (13/16), and levofloxacin‐based rescue therapy was 66.7% (2/3).
Conclusion
Re‐treatment of patients with H. pylori reinfection with STT had limited efficacy. Prospective research is needed to determine whether patients with non‐ulcer dyspepsia are vulnerable to reinfection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, St. Vincent Hospital, The Catholic University of Korea, Suwon, South Korea.
ORCID-Profile: Na Rae Lim, Woo Chul Chung
Zitieren
APA
Lim, N. R., Kim, J., & Chung, W. C. (2024). Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients. Helicobacter. https://doi.org/10.1111/hel.13036
Vancouver
Lim NR, Kim J, Chung WC. Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients. Helicobacter. 2024. doi:10.1111/hel.13036
BibTeX
@article{Lim2024,
author = {Lim, Na Rae and Kim, Jiyoung and Chung, Woo Chul},
title = {Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13036}
}
EUVIMED